echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Experts review the 2020 health care policy Understand the 2021 policy direction!

    Experts review the 2020 health care policy Understand the 2021 policy direction!

    • Last Update: 2021-01-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network January 22nd 2020 is the year of the 13th Five-Year Plan, the year of the 14th Five-Year Plan is about to open, is the year of the common fight against the epidemic, the entire pharmaceutical industry policy in the outbreak prevention and control and resumption of work, continue to deepen the reform of the medical and health system, medical insurance, medical care, medicine, the three medical links further advanced.
    the past, see the future, review the 2020 pharmaceutical industry policy, explore new opportunities, find new ways out.
    review the 2020 health care policy today to explore trends in 2021.
    2020 health insurance policy is mainly set in the health insurance catalog adjustment, centralized procurement, health insurance payment three aspects.
    on March 5, 2020, the State Council officially issued the Opinions on Deepening the Reform of the Medical Security System, proposing to adjust and optimize the medical insurance catalogue, including drugs with high clinical value and excellent economic evaluation, medical treatment projects and medical supplies into the scope of medical insurance payments, and standardize the scope of payment of medical service facilities.
    the dynamic adjustment mechanism of the medical insurance catalogue and improve the system of medical insurance access negotiation.
    July 31, 2020, the State Administration of Health Insurance issued the Interim Measures for the Administration of Drug Use in Basic Medical Insurance, which clarified the scope and method of payment of medical insurance funds, and the criteria and scope for the transfer of medicines into and out of the Medical Insurance Directory.
    August 17, 2020, the International Health Insurance Bureau officially released the 2020 National Health Insurance Directory Adjustment Work Programme, and simultaneously issued the 2020 National Health Insurance Drug Catalog Adjustment Reporting Guidelines, the 2020 health insurance catalog adjustment work officially started.
    on December 28, 2020, the 2020 edition of the health insurance program will be released, will be officially implemented on March 1 this year.
    162 drugs were negotiated in the catalogue and 119 were successful, including 96 exclusive drugs, with a success rate of 73.46 per cent.
    national health care negotiations is one of the ways to access the health insurance catalog, so far the health care negotiations have been carried out a total of 4 times and a pilot.
    Health care negotiations over the years overview table and the 2020 health care adjustment is the most interesting point of concern is innovative drugs, especially single anti-PD-(L)1, domestic listed products are all involved in the negotiations, the original research has not been successfully negotiated, domestic PD-(L)1 all included (Thyda Pharmaceuticals Daboshu ®2018 negotiations into health care).
    fact, in recent years, the adjustment of the health insurance catalog has highlighted the encouragement of innovation, innovative drugs have been a hot topic of negotiation, because innovative drugs into the health insurance payment system is the most direct and effective way to expand the market to increase usage.
    with the normalization of the health insurance catalog, more and more innovative drugs will be included in the catalog in the future, and it will be an opportunity and a challenge for innovative research and development enterprises.
    Shuguang, general manager of Trump Reiter Pharmaceuticals, said that innovative drugs are included in health insurance to the good of the country, pharmaceutical companies, people, the essence of drugs is to cure and save people.
    Innovating drugs into health insurance, for pharmaceutical companies, drug sales have been guaranteed, for patients, drug use has been affordable, for the country, can effectively control drug prices, so that patients can take medicines, affordable medicines.
    In fact, after the launch of any new drug, there is a long period of climbing, the need to recover research and development costs, often the price of new drugs is relatively high, the price of innovative drugs can be included in the health insurance catalog through health care negotiations soon after the market, the state procurement, fast and efficient to ensure the sale of innovative drugs, while encouraging pharmaceutical companies for innovative drug research and development.
    For the 2020 health care negotiations domestic PD-(L)1 all into health insurance, and the original research enterprises did not enter, he said, to some extent, for domestic enterprises is an encouragement, a support, an endorsement, the country is also a protection, can promote the rapid recovery of the cost of local pharmaceutical companies to develop drugs, and then more funds and confidence into more innovative drug research and development For foreign-funded enterprises, it is a kind of stimulus whipping effect, invisibly raised the "threshold" for foreign pharmaceutical companies to enter the Chinese market innovative drugs: First, to force foreign-funded enterprises to adjust their strategies, reduce the price of the original research products, to "price" the "market", and second, to promote foreign-funded enterprises will have more unique and innovative target drugs, and no new drugs introduced into China.
    In addition, Dr. Hou Shuguang said, through the national drug collection, the pressure of the medical insurance funding burden has been significantly released and reduced, more funds to bear more drugs into the health insurance catalog, in the future, the health insurance catalog will be further liberalized, so that more people in the past can not see the drug into the Medical insurance, further enrich the contents of the catalog, while chain stimulation, promote more enterprises to imitate the emergence of new drugs, further make drug prices lower, to the interests of the country and the people;
    health insurance control fees, centralized procurement of the fourth batch of comprehensive collection reduction will not be less than 50%, if 2019 is a key year for drug centralized procurement innovation, 2020 is a comprehensive spread of drug centralized procurement of the year.
    Injection consistency evaluation officially began, so far dozens of injections have been evaluated, supporting policies and "medical prices and credit evaluation system guidance" and other issues, for medical insurance charges, centralized procurement in-depth promotion of escort.
    On January 17, 2020, the results of the second batch of centralized drug procurement work of the national organization were announced 33 varieties of 122 enterprises to run for election, the final 32 varieties of 77 enterprises to be selected, compared with the lowest purchase price in the Alliance region in 2018, the average price of the proposed selection decreased by 53%;
    July 29, 2020, Shanghai Sunshine Pharmaceutical Procurement Network announced the official document of the national centralized procurement of drugs, the third batch of national collection officially began.
    August 20, the third round of the national drug centralized procurement declaration information open conference held in Shanghai, the same night Shanghai Joint Procurement Office released the third batch of national collection and selection results, 55 varieties of winning bids, 128 selected pharmaceutical enterprises, the average price reduction of 53%, the maximum price reduction of more than 95%.
    The national drug centralized procurement overview drug collection normalization mechanism gradually appeared, the number of collecting varieties increased, the scope of application of drugs expanded, and extended to pharmaceutical supplies, last November 8 manufacturers in 1.07 million crown vein stents selected to obtain the national collection, a drop of up to 94%.
    Subsequently, on December 25, 2020, Shanghai Sunshine Pharmaceutical Procurement Network, the Joint Procurement Office issued a "Notice on the implementation of the fourth batch of national organizations centralized procurement of drugs related to drug information collection work", 90 varieties were shortlisted, the largest number of previous collections, injections added to the collection.
    January 12, the National Conference on Medical Security was held in Beijing by video, and one of the key efforts in 2021 will be to implement centralized tenders for the continuous institutionalization and normalization of drug supplies.
    January 15, CCTV News broadcast the key contents of the executive meeting of the State Council, further promote the reform of drug centralized belt procurement, with normal institutional measures to reduce the burden of medical treatment for the masses, while Shanghai Sunshine Pharmaceutical Procurement Network published the fourth batch of collection documents and procurement catalogues.
    For the collection of normal system, industry experts talk about Zhang Tingjie said, whether it is national or local with volume mining, every year there are provinces, in fact, has been the norm;
    Pharma industry senior observer Feng light said, in the face of the normal development of collection, enterprises only do their own internal work, there is no other way, now the fourth batch of collection began, enterprises need to do a good job of product layout, including their own product raw materials, the average decline is expected to be no less than 50%.
    addition, the fourth batch of collection for the first time included a variety of clinically commonly used injections, under the normal mechanism of collection, he said, injections will be the 2021 provincial belt procurement focus on varieties.
    Health insurance payment, DRG and DIP parallel development of effective treatment basic cost savings is the third important key word of the principle 2020 health care policy, is health insurance payment, and the establishment of effective health insurance payment mechanism, DRG and DIP two payment methods become the key to the reform of health insurance payment.
    In 2019, the National Health Insurance Administration has developed a DRG top-level planning and grouping program to promote reform in accordance with the "top-level design, simulation testing, actual payment" three-step approach to the three-step approach;
    In addition to DRG, on October 19, 2020, the State Health Insurance Administration issued the "Pilot Work Programme on The Total Budget of the Regional Points Law and Paying by The Value of Diseases", which clearly uses 1-2 years to combine the total regional medical insurance budget with the points method to realize the multi-composite payment method based on the value-among diseases in hospitals, and by the end of 2021, all pilot areas will have entered the actual payment phase.
    November 3, 2020, the State Drug Administration announced that 71 cities in 27 provinces had been included in the DIP (pay-per-disease) pilot and announced a list of 200 DIP experts.
    number of pilot cities, DIP pilot far exceeds DRGs pilot cities, which shows the country's determination to implement DIP.
    the biggest link and difference between the two? How can our country effectively push forward the reform of the two payment methods at this stage? How to integrate development? Duchen, a strategic management expert and china CEO coach, said DIP could actually be seen as an upgraded version of DRG, and that Europe and the United States and Japan had long implemented a pay-per-disease approach, and now China is also trying to pilot it.
    DIP is based on big data and is directly related to the development of network technologies such as computers and new IT technologies, and should be a way to pay for diseases under new IT technologies.
    the bottom frame of the two payment methods, DRG and DIP, is the same, the biggest difference is that DIP is more accurate and timely due to the introduction of big data.
    Duchen said that China's DRG and DIP payment reform is very necessary to promote better, at this stage, the state has been promoting the transformation of medical institutions mechanism, from doctors willing to open more prescriptions to more willing to open more effective drugs, from their own interests to save health insurance funds.
    we actively promote the reform of the payment method? "First of all, we should objectively summarize the experience and lessons learned in the last three years or so in the reform of payment methods and payment methods, analyze the achievements and problems clearly in order to effectively and accurately promote the reform of the system; Third, the application of the latest big data network technology and IT technology armed payment method reform, will bring more convenience, with the progress of network data technology, data algorithm improvement, payment method reform should be implemented in the shortest possible time, that is, DIP payment method gradually implemented, and the country as far as possible to implement a model, although different hospitals have different payment methods, but should maintain the overall format and framework consistent, standards unified.
    In addition, he pointed out that the reform of the payment method, in fact, involves the transformation of the internal mechanism of medical institutions, the current medical institutions are also reforming, including the number of doctors, career fixed-point and a series of ways, therefore, the reform of the payment method and the reform of the internal mechanism of medical institutions should be a coordinated and systematic reform, if the internal reform of medical institutions is not systematically advanced, then the reform of the payment method is impossible to complete.
    In addition, he stressed that DRG and DIP two payment methods should have a clear goal, the key core is to be able to effectively treat patient diseases, play a life-saving injury to solve the practical problem of patient care expensive, once deflected, may only be medical institutions to save costs and save costs, therefore, should be based on more effective treatment to save costs as the basic principle of medical payment reform.
    know the past and see the future.
    the year of the 14th Five-Year Plan in 2021, the new version of the medical insurance catalog implementation of the first year, the national base drug catalog adjustment year, the centralized procurement of drugs fully rolled out, the implementation of the normal mechanism, DRG and DIP payment reform acceleration.... As the changes continue, the medical people will still need to move forward in 2021.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.